{"id":35443,"date":"2026-03-25T15:59:10","date_gmt":"2026-03-25T15:59:10","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/35443\/"},"modified":"2026-03-25T15:59:10","modified_gmt":"2026-03-25T15:59:10","slug":"nejvetsi-experiment-v-dejinach-hubnuti-prave-zacal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/35443\/","title":{"rendered":"Nejv\u011bt\u0161\u00ed experiment v\u00a0d\u011bjin\u00e1ch hubnut\u00ed pr\u00e1v\u011b za\u010dal"},"content":{"rendered":"

V p\u00e1tek 21.\u00a0b\u0159ezna vypr\u0161el v\u00a0Indii patent na semaglutid, \u00fa\u010dinnou l\u00e1tku p\u0159\u00edpravk\u016f Ozempic a\u00a0Wegovy od d\u00e1nsk\u00e9ho v\u00fdrobce l\u00e9k\u016f Novo Nordisk. B\u011bhem n\u011bkolika hodin za\u010dalo v\u00edce ne\u017e \u010dty\u0159icet firem<\/a> prod\u00e1vat vlastn\u00ed verze l\u00e9ku.<\/p>\n

Cenov\u00e1 v\u00e1lka v\u00a0Indii je mimo\u0159\u00e1dn\u011b ostr\u00e1. Ceny klesly doslova p\u0159es noc<\/a> o\u00a060\u00a0a\u017e 90\u00a0procent. Sun Pharma nab\u00edz\u00ed svou verzi za 750\u00a0rupi\u00ed t\u00fddn\u011b (cca 170\u00a0korun), Natco Pharma prod\u00e1v\u00e1 lahvi\u010dky od 1\u00a0290\u00a0rupi\u00ed m\u011bs\u00ed\u010dn\u011b (cca 300\u00a0korun), firma Eris Lifesciences p\u0159i\u0161la s\u00a0cenou 220\u00a0rupi\u00ed za jednu d\u00e1vku\u00a0\u2013 necel\u00fdch 60\u00a0korun<\/a>. Zna\u010dkov\u00fd Ozempic p\u0159itom v\u00a0Indii st\u00e1l kolem 9\u00a0tis\u00edc\u00a0rupi\u00ed, tedy 2\u00a0tis\u00edc\u00a0korun (ne\u017e Novo Nordisk p\u0159ed vypr\u0161en\u00edm patentu sn\u00ed\u017eil ceny sv\u00fdch zna\u010dkov\u00fdch p\u0159\u00edpravk\u016f o\u00a0v\u00edce ne\u017e t\u0159etinu).<\/p>\n

Cynicky \u0159e\u010deno, sou\u010dasn\u00e9 ceny jsou podobn\u00e9 jako \u010d\u00e1stka, kterou pacient u\u0161et\u0159\u00ed za m\u011bs\u00edc na potravin\u00e1ch, kdy\u017e p\u0159\u00edpravek sni\u017euj\u00edc\u00ed chu\u0165 k\u00a0j\u00eddlu za\u010dne u\u017e\u00edvat. <\/p>\n

Potenci\u00e1l p\u0159itom nen\u00ed mal\u00fd; indick\u00fd trh s\u00a0l\u00e9ky proti obezit\u011b vzrostl za p\u011bt let p\u011btin\u00e1sobn\u011b<\/a>. Zem\u011b m\u00e1 sto milion\u016f diabetik\u016f a\u00a0zhruba \u010dtvrtinu dosp\u011bl\u00e9 populace s\u00a0nadv\u00e1hou nebo obezitou. Dosud si modern\u00ed l\u00e9ky mohl dovolit m\u00e1lokdo; te\u010f je m\u016f\u017ee p\u0159edepsat prakticky ka\u017ed\u00fd l\u00e9ka\u0159 a\u00a0pacient za n\u011b zaplat\u00ed \u010d\u00e1stku srovnatelnou s\u00a0m\u011bs\u00ed\u010dn\u00edm p\u0159edplatn\u00fdm streamovac\u00ed slu\u017eby.<\/p>\n

Indie je ale jen za\u010d\u00e1tek. V\u00a0nadch\u00e1zej\u00edc\u00edch m\u011bs\u00edc\u00edch vypr\u0161\u00ed patent tak\u00e9 v\u00a0\u010c\u00edn\u011b, kde m\u00e1 v\u00a0z\u00e1v\u011bre\u010dn\u00e9 f\u00e1zi schvalov\u00e1n\u00ed p\u0159es deset kopi\u00ed, a\u00a0d\u00e1le v\u00a0Braz\u00edlii, Turecku a\u00a0Jihoafrick\u00e9 republice. Dohromady jde o\u00a0zem\u011b p\u0159edstavuj\u00edc\u00ed asi 40\u00a0procent<\/a> sv\u011btov\u00e9 populace a\u00a0zhruba t\u0159etinu v\u0161ech dosp\u011bl\u00fdch \u017eij\u00edc\u00edch s\u00a0obezitou.<\/p>\n

Je to historicky ojedin\u011bl\u00e1 situace. V\u00fdzkumn\u00edci odhaduj\u00ed, \u017ee semaglutid je mo\u017en\u00e9 masov\u011b vyr\u00e1b\u011bt za cenu kolem t\u0159\u00ed dolar\u016f<\/a> m\u011bs\u00ed\u010dn\u011b na pacienta. To, co se pr\u00e1v\u011b odehr\u00e1v\u00e1, je sv\u00e9ho druhu p\u0159irozen\u00fd experiment. A\u00a0jeho v\u00fdsledky ovlivn\u00ed i\u00a0\u010cesko a\u00a0dal\u0161\u00ed zem\u011b, kter\u00e9 si na levn\u011bj\u0161\u00ed verze budou muset je\u0161t\u011b roky po\u010dkat.<\/p>\n

Co je semaglutid a\u00a0pro\u010d funguje<\/p>\n

Pro \u010dten\u00e1\u0159e, kte\u0159\u00ed v\u00fdvoj t\u011bchto l\u00e9k\u016f nesledovali od za\u010d\u00e1tku\u00a0\u2013 jejich p\u0159\u00edb\u011bh jsme podrobn\u011b popsali d\u0159\u00edve<\/a>. Semaglutid napodobuje hormon GLP-1, kter\u00fd na\u0161e st\u0159evo vypou\u0161t\u00ed po j\u00eddle. Potla\u010duje chu\u0165 k\u00a0j\u00eddlu, zpomaluje tr\u00e1ven\u00ed, reguluje hladinu cukru v\u00a0krvi. Nefunguje \u00fapln\u011b u\u00a0ka\u017ed\u00e9ho, ale zhruba u\u00a080\u00a0% t\u011bch, kdo ho vyzkou\u0161\u00ed, ano. <\/p>\n

P\u016fvodn\u011b \u0161lo o\u00a0l\u00e9k na cukrovku druh\u00e9ho typu, schv\u00e1len\u00fd v\u00a0roce 2017\u00a0pod n\u00e1zvem Ozempic. \u017de pacienti v\u00fdrazn\u011b hubnou, byl ne\u010dekan\u00fd vedlej\u0161\u00ed efekt. V\u00a0roce 2021\u00a0americk\u00e1 FDA schv\u00e1lila vy\u0161\u0161\u00ed d\u00e1vku pod n\u00e1zvem Wegovy p\u0159\u00edmo k\u00a0l\u00e9\u010db\u011b obezity. V\u00a0klinick\u00fdch studi\u00edch vedl k\u00a0\u00fabytku zhruba 15\u00a0% hmotnosti za necel\u00fd rok a\u00a0p\u016fl a\u00a0funguje u\u00a0p\u0159ibli\u017en\u011b 80\u00a0% pacient\u016f.<\/p>\n

<\/a><\/p>\n

Z\u00e1sadn\u00ed je ov\u0161em jedno \u201eale\u201c: po vysazen\u00ed se v\u00e1ha vrac\u00ed. Dv\u011b velk\u00e9 studie z\u00a0roku 2025\u00a0\u2013 jedna z\u00a0nich publikovan\u00e1 v\u00a0Lancetu<\/a>\u00a0\u2013 potvrdily, \u017ee v\u00a0prvn\u00edm roce po vysazen\u00ed pacienti nabrali dv\u011b t\u0159etiny shozen\u00e9 hmotnosti zp\u011bt a\u00a0ve t\u0159et\u00edm roce p\u0159ib\u00edr\u00e1n\u00ed pokra\u010dovalo. L\u00e9ka\u0159i proto st\u00e1le d\u016frazn\u011bji mluv\u00ed o\u00a0obezit\u011b jako o\u00a0chronick\u00e9 nemoci srovnateln\u00e9 s\u00a0vysok\u00fdm krevn\u00edm tlakem.<\/p>\n

\u201eP\u016fvodn\u011b se myslelo, \u017ee do\u010dasn\u00e9 u\u017e\u00edv\u00e1n\u00ed p\u0159enastav\u00ed metabolismus trvale. Ale to se bohu\u017eel nepotvrdilo,\u201c \u0159\u00edk\u00e1 obezitolo\u017eka Dita Pichlerov\u00e1 z\u00a0Fakultn\u00ed nemocnice Motol pro Seznam Zpr\u00e1vy<\/a>. L\u00e9ky je tedy t\u0159eba br\u00e1t dlouhodob\u011b, stejn\u011b jako t\u0159eba medikamenty na vysok\u00fd krevn\u00ed tlak.<\/p>\n

Dva patentov\u00e9 sv\u011bty<\/p>\n

Z\u00e1kladn\u00ed patent na semaglutid byl p\u0159ihl\u00e1\u0161en v\u00a0b\u0159eznu 2006.\u00a0Standardn\u00ed dvacetilet\u00e1 ochrana tedy kon\u010d\u00ed v\u00a0b\u0159eznu 2026\u00a0a\u00a0v Indii, \u010c\u00edn\u011b nebo Braz\u00edlii tomu tak skute\u010dn\u011b je\u00a0\u2013 tyto zem\u011b toti\u017e nemaj\u00ed mechanismy, kter\u00e9 by ji prodlou\u017eily.<\/p>\n

V Evropsk\u00e9 unii ale existuje takzvan\u00fd dodatkov\u00fd ochrann\u00fd certifik\u00e1t<\/a> (SPC), kter\u00fd prodlu\u017euje patentovou ochranu o\u00a0maxim\u00e1ln\u011b p\u011bt let jako kompenzaci za dobu str\u00e1venou schvalov\u00e1n\u00edm l\u00e9ku. Smysl je logick\u00fd: farmaceutick\u00e1 firma pod\u00e1 patent, ale ne\u017e l\u00e9k projde klinick\u00fdmi zkou\u0161kami a\u00a0regula\u010dn\u00edm procesem, uplyne z\u00a0dvacetilet\u00e9 ochrany \u0159ada let. SPC \u010d\u00e1st t\u00e9to ztr\u00e1ty vynahrazuje. Pro semaglutid je v\u00a0Evrop\u011b ud\u011blen do b\u0159ezna 2031.\u00a0V\u00a0USA funguje obdobn\u00fd mechanismus, v\u00a0tomto p\u0159\u00edpad\u011b tak\u00e9 do konce roku 2031.<\/p>\n

Sv\u011bt se proto v\u00a0ot\u00e1zce p\u0159\u00edstupu k\u00a0t\u011bmto l\u00e9k\u016fm roz\u0161t\u011bpil na dv\u011b \u010d\u00e1sti. Na jedn\u00e9 stran\u011b zem\u011b, kde budou kopie za zlomek dosavadn\u00ed ceny, na druh\u00e9 USA a\u00a0EU, kde si Novo Nordisk zachov\u00e1 monopol dal\u0161\u00edch p\u011bt let<\/a>.<\/p>\n

Situace je ov\u0161em p\u0159ece jen slo\u017eit\u011bj\u0161\u00ed, ne\u017e se na prvn\u00ed pohled zd\u00e1. Novo Nordisk disponuje rozs\u00e1hl\u00fdm portfoliem takzvan\u00fdch sekund\u00e1rn\u00edch patent\u016f, kter\u00e9 chr\u00e1n\u00ed konkr\u00e9tn\u00ed d\u00e1vkov\u00e1n\u00ed, aplika\u010dn\u00ed za\u0159\u00edzen\u00ed nebo jednotliv\u00e9 indikace.<\/p>\n

Podle anal\u00fdzy neziskov\u00e9 organizace I-MAK<\/a> m\u00e1 firma 154\u00a0ud\u011blen\u00fdch americk\u00fdch patent\u016f souvisej\u00edc\u00edch se semaglutidem, z\u00a0nich\u017e 49\u00a0vypr\u0161\u00ed a\u017e po hlavn\u00edm patentu; n\u011bkter\u00e9 sahaj\u00ed a\u017e do roku 2042.\u00a0A\u00a0firma se pere o\u00a0ka\u017ed\u00fd z\u00a0nich: jen v\u00a0\u0159\u00edjnu 2025\u00a0si v\u00a0Evrop\u011b vymohla 26\u00a0p\u0159edb\u011b\u017en\u00fdch soudn\u00edch z\u00e1kaz\u016f za poru\u0161en\u00ed jednoho ze sv\u00fdch patent\u016f<\/a>.<\/p>\n

<\/a><\/p>\n

Na druhou stranu se ochrana drol\u00ed i\u00a0tam, kde m\u011bla b\u00fdt nejpevn\u011bj\u0161\u00ed. Evropsk\u00fd patentov\u00fd \u00fa\u0159ad v\u00a0roce 2024\u00a0zru\u0161il dva kl\u00ed\u010dov\u00e9 patenty Novo Nordisk na or\u00e1ln\u00ed formu semaglutidu, a\u00a0to na z\u00e1klad\u011b n\u00e1mitek konkurent\u016f<\/a>. Od\u016fvodn\u011bn\u00ed: patentovan\u00e1 kombinace d\u00e1vky a\u00a0formulace nebyla dostate\u010dn\u011b vyn\u00e1lezeck\u00e1. I\u00a0kdy\u017e jde o \u201ez\u00e1zra\u010dn\u00fd l\u00e9k\u201c, patentovou ochranu to automaticky nezaru\u010duje, konstatoval odvolac\u00ed sen\u00e1t.<\/p>\n

Cesta na trh tedy nebude pro v\u00fdrobce kopi\u00ed v\u0161ude jednoduch\u00e1. D\u00e1 se o\u010dek\u00e1vat \u0159ada soudn\u00edch spor\u016f. Ale z\u00e1jem je obrovsk\u00fd\u00a0\u2013 jen v\u00a0Indii se na startovn\u00ed \u010d\u00e1ru<\/a> postavilo p\u0159es \u010dty\u0159icet firem s\u00a0v\u00edce ne\u017e pades\u00e1ti zna\u010dkami.<\/p>\n

Dodejme, \u017ee Novo Nordisk (a dal\u0161\u00ed velk\u00e9 firmy) nespol\u00e9h\u00e1 jen na soudy. V\u00a0prosinci 2025\u00a0podalo u\u00a0americk\u00e9 FDA \u017e\u00e1dost o\u00a0schv\u00e1len\u00ed CagriSemy<\/a>, kombinace semaglutidu s\u00a0cagrilintidiem, kter\u00e1 v\u00a0klinick\u00fdch studi\u00edch dos\u00e1hla \u00fabytku hmotnosti 22,7\u00a0% za 68\u00a0t\u00fddn\u016f. FDA by m\u011bla rozhodnout v\u00a0druh\u00e9 polovin\u011b leto\u0161n\u00edho roku. Soub\u011b\u017en\u011b firma \u010dek\u00e1 na schv\u00e1len\u00ed or\u00e1ln\u00ed formy semaglutidu pro obezitu.<\/p>\n

Strategie je z\u0159ejm\u00e1: p\u0159esunout pacienty na nov\u011bj\u0161\u00ed, patentov\u011b chr\u00e1n\u011bn\u00e9 p\u0159\u00edpravky d\u0159\u00edve, ne\u017e vypr\u0161\u00ed ochrana t\u011bch sou\u010dasn\u00fdch. Stejnou cestou jde Eli Lilly<\/a> s\u00a0tirzepatidem a\u00a0dal\u0161\u00edmi molekulami nov\u00e9 generace.<\/p>\n

Co u\u017e v\u00edme z\u00a0Ameriky<\/p>\n

Ve Spojen\u00fdch st\u00e1tech, kde semaglutid zat\u00edm o\u00a0monopol nep\u0159i\u0161el, ale kde si ho m\u016f\u017ee dovolit podstatn\u00e1 \u010d\u00e1st populace, u\u017e se efekt projevuje. Podle Gallupova<\/a> pr\u016fzkumu z\u00a0roku 2025\u00a0klesla m\u00edra obezity z\u00a0rekordn\u00edch 39,9\u00a0% v\u00a0roce 2022\u00a0na 37\u00a0%. To znamen\u00e1, \u017ee ob\u00e9zn\u00edch dosp\u011bl\u00fdch by m\u011blo b\u00fdt zhruba o\u00a07,6\u00a0milionu m\u00e9n\u011b. Sou\u010dasn\u011b se pod\u00edl Ameri\u010dan\u016f u\u017e\u00edvaj\u00edc\u00edch GLP-1\u00a0p\u0159\u00edpravky v\u00edce ne\u017e zdvojn\u00e1sobil na 12,4\u00a0%.<\/p>\n

Nejv\u011bt\u0161\u00ed pokles obezity je ve v\u011bkov\u00e9 skupin\u011b \u010dty\u0159ic\u00e1tn\u00edk\u016f a\u017e \u0161edes\u00e1tn\u00edk\u016f, tedy u\u00a0t\u011bch, kdo u\u017e\u00edvaj\u00ed nejv\u00edce l\u00e9k\u016f. Korelace je siln\u00e1, i\u00a0kdy\u017e p\u0159\u00edsn\u00fd kauz\u00e1ln\u00ed d\u016fkaz zat\u00edm chyb\u00ed (data vych\u00e1zej\u00ed ze sebehodnocen\u00ed<\/a>).<\/p>\n

Dodejme, \u017ee pokles v\u00fdskytu obezity se zat\u00edm neprom\u00edtl do poklesu p\u0159\u00edpad\u016f cukrovky. Ta v\u00a0USA naopak dos\u00e1hla rekordu 13,8\u00a0%. Jakmile je \u010dlov\u011bk jednou diagnostikov\u00e1n jako diabetik, z\u016fst\u00e1v\u00e1 v\u00a0kategorii bez ohledu na pozd\u011bj\u0161\u00ed zhubnut\u00ed. Efekt na nov\u00e9 p\u0159\u00edpady se m\u016f\u017ee projevit a\u017e za roky.<\/p>\n

V \u010cesku nic takov\u00e9ho zat\u00edm nevid\u00edme. Podle profesora Martina Haluz\u00edka z\u00a0IKEM l\u00e9ky u\u017e\u00edv\u00e1 asi 80\u00a0a\u017e 100\u00a0tis\u00edc pacient\u016f, tedy zhruba jedno procento populace\u00a0\u2013 oproti 12,4\u00a0% v\u00a0USA. Hlavn\u00ed p\u0159ek\u00e1\u017ekou z\u016fst\u00e1v\u00e1 cena: nejmodern\u011bj\u0161\u00ed p\u0159\u00edpravky stoj\u00ed mezi 3\u00a0500\u00a0a\u00a010\u00a0500\u00a0korun m\u011bs\u00ed\u010dn\u011b<\/a> p\u0159i l\u00e9\u010db\u011b obezity, p\u0159i\u010dem\u017e by z\u00a0nich m\u011blo prosp\u011bch odhadem 2,4\u00a0milionu lid\u00ed. Spot\u0159eba p\u0159itom roste: v\u00a0roce 2022\u00a0dodali v\u00fdrobci p\u0159es p\u016fl milionu balen\u00ed GLP-1\u00a0l\u00e9k\u016f, loni u\u017e p\u0159es 1,3\u00a0milionu.<\/p>\n

<\/a>Jak l\u00e9ky m\u011bn\u00ed j\u00eddlo, pit\u00ed i\u00a0pohyb<\/p>\n

Co se stane, a\u017e za\u010dnou l\u00e9ky u\u017e\u00edvat des\u00edtky \u010di dokonce mo\u017en\u00e1 stovky milion\u016f lid\u00ed v\u00a0Indii, \u010c\u00edn\u011b \u010di Braz\u00edlii? \u00da\u010dinek GLP-1\u00a0p\u0159\u00edpravk\u016f je toti\u017e v\u00fdrazn\u011b pest\u0159ej\u0161\u00ed, ne\u017e by n\u00e1lepka \u201el\u00e9k na obezitu a\u00a0cukrovku\u201c napov\u00eddala.<\/p>\n

Dopady m\u016f\u017ee nap\u0159\u00edklad poc\u00edtit potravin\u00e1\u0159sk\u00fd pr\u016fmysl. Studie Cornellovy univerzity publikovan\u00e1 v\u00a0Journal of Marketing Research v\u00a0prosinci 2025\u00a0analyzovala transak\u010dn\u00ed data des\u00edtek tis\u00edc americk\u00fdch dom\u00e1cnost\u00ed a\u00a0zjistila, \u017ee po zah\u00e1jen\u00ed u\u017e\u00edv\u00e1n\u00ed GLP-1\u00a0klesly v\u00fddaje za potraviny o\u00a05,3\u00a0%<\/a>, u\u00a0vy\u0161\u0161\u00edch p\u0159\u00edjmov\u00fdch skupin o\u00a0v\u00edce ne\u017e 8\u00a0%. V\u00fddaje za fast food klesly tak\u00e9 o\u00a08\u00a0%. Nejv\u00edc se sn\u00ed\u017eily n\u00e1kupy slan\u00fdch \u201esnack\u016f\u201c, sladkost\u00ed a\u00a0pe\u010diva; m\u00edrn\u011b vzrostly naopak n\u00e1kupy jogurt\u016f a\u00a0\u010derstv\u00e9ho ovoce.<\/p>\n

Po vysazen\u00ed l\u00e9ku se vzorce vr\u00e1tily\u00a0\u2013 a\u00a0n\u00e1kupy sladkost\u00ed se dokonce m\u00edrn\u011b zv\u00fd\u0161ily nad p\u016fvodn\u00ed \u00farove\u0148. Profesor Haluz\u00edk popisuje tot\u00e9\u017e v\u00a0\u010desk\u00e9m kontextu: pacienti p\u0159estanou chodit do fast food\u016f, cht\u011bj\u00ed sal\u00e1ty a\u00a0vyv\u00e1\u017eenou stravu. Obvod pasu se jim m\u016f\u017ee zmen\u0161it o\u00a0dvacet centimetr\u016f.<\/p>\n

M\u00e9n\u011b p\u0159\u00edmo\u010dar\u00e1 je odpov\u011b\u010f na ot\u00e1zku, co to ud\u011bl\u00e1 se vztahem k\u00a0pohybu. L\u00e9ka\u0159i se opr\u00e1vn\u011bn\u011b ob\u00e1vaj\u00ed, \u017ee kdo hubne \u201einjekc\u00ed\u201c, bude m\u00e9n\u011b cvi\u010dit\u00a0\u2013 a\u00a0pohyb p\u0159itom m\u00e1 tolik p\u0159\u00ednos\u016f, \u017ee nem\u00e1me \u010das je ani stru\u010dn\u011b vyjmenovat.<\/p>\n

Z klinick\u00fdch studi\u00ed p\u0159itom vypl\u00fdv\u00e1 re\u00e1ln\u00fd probl\u00e9m: p\u0159i rychl\u00e9m hubnut\u00ed na GLP-1\u00a0tvo\u0159\u00ed ztr\u00e1ta svalov\u00e9 hmoty 25\u00a0a\u017e 40\u00a0%<\/a> celkov\u00e9ho \u00fabytku v\u00e1hy. To je srovnateln\u00e9 s\u00a0\u00fabytkem sval\u016f, k\u00a0jak\u00e9mu u\u00a0zdrav\u00e9ho \u010dlov\u011bka dojde za cel\u00e9 desetilet\u00ed st\u00e1rnut\u00ed. \u017deny a\u00a0star\u0161\u00ed pacienti jsou ohro\u017eeni nejv\u00edce<\/a>. Harvard\u0161t\u00ed v\u011bdci proto d\u016frazn\u011b doporu\u010duj\u00ed kombinovat l\u00e9ky s\u00a0posilovac\u00edm cvi\u010den\u00edm a\u00a0zv\u00fd\u0161en\u00fdm p\u0159\u00edjmem<\/a> b\u00edlkovin.<\/p>\n

Ale z\u00a0praxe zn\u00e1me i\u00a0opa\u010dn\u00fd efekt: n\u011bkte\u0159\u00ed pacienti, kte\u0159\u00ed kv\u016fli sv\u00e9 v\u00e1ze nemohli nebo necht\u011bli cvi\u010dit, za\u010dnou po zhubnut\u00ed se sportem. P\u0159\u00edpadov\u00e1 studie z\u00a0roku 2025\u00a0dokumentovala, \u017ee pacienti kombinuj\u00edc\u00ed l\u00e9ky se silov\u00fdm tr\u00e9ninkem si svalovou hmotu zachovali<\/a>\u00a0\u2013 dva ze t\u0159\u00ed ji dokonce zv\u00fd\u0161ili. Kter\u00fd z\u00a0nich v\u00a0praxi nakonec p\u0159evl\u00e1dne, je\u0161t\u011b uvid\u00edme. V\u00fdsledek je t\u011b\u017eko p\u0159edv\u00eddateln\u00fd, proto\u017ee nez\u00e1vis\u00ed \u010dist\u011b na biologii, ale i\u00a0na p\u0159evl\u00e1daj\u00edc\u00edch n\u00e1zorech, zvyc\u00edch a\u00a0p\u0159esv\u011bd\u010den\u00ed.<\/p>\n

<\/a><\/p>\n

Zaj\u00edmav\u00e9 bude sledovat i\u00a0to, co se stane s\u00a0ne\u0159estmi. Ned\u00e1vno zve\u0159ejn\u011bn\u00e9 v\u00fdsledky nazna\u010duj\u00ed, \u017ee u\u00a0lid\u00ed na GLP-1\u00a0se alkohol v\u00a0t\u011ble vst\u0159eb\u00e1v\u00e1 pomaleji<\/a> a\u00a0jeho p\u0159\u00edjemn\u00e9 \u00fa\u010dinky nastupuj\u00ed pozd\u011bji\u00a0\u2013 co\u017e m\u016f\u017ee vysv\u011btlovat, pro\u010d pro \u0159adu z\u00a0nich p\u0159est\u00e1v\u00e1 b\u00fdt p\u0159ita\u017eliv\u00fd. Podle zku\u0161enost\u00ed<\/a> Dity Pichlerov\u00e9 u\u00a0pacient\u016f doch\u00e1z\u00ed i\u00a0ke sn\u00ed\u017een\u00ed chuti na cigarety.<\/p>\n

Rozs\u00e1hl\u00e1 popula\u010dn\u00ed studie publikovan\u00e1 v\u00a0BMJ<\/a> jde je\u0161t\u011b d\u00e1l: GLP-1\u00a0l\u00e9ky mohou pom\u00e1hat nejen proti alkoholu, ale i\u00a0proti kokainu a\u00a0opioid\u016fm. A\u00a0u lid\u00ed, kte\u0159\u00ed u\u017e z\u00e1vislost\u00ed trp\u011bli, bylo riziko \u00famrt\u00ed na zneu\u017e\u00edv\u00e1n\u00ed n\u00e1vykov\u00fdch l\u00e1tek ni\u017e\u0161\u00ed o\u00a050\u00a0%.<\/p>\n

Mechanismus z\u0159ejm\u011b souvis\u00ed s\u00a0t\u00edm, \u017ee GLP-1\u00a0receptory se nach\u00e1zej\u00ed v\u00a0mozkov\u00fdch oblastech \u0159\u00edd\u00edc\u00edch odm\u011bnu a\u00a0motivaci\u00a0\u2013 l\u00e9k tedy \u201eztlum\u00ed\u201c nejen chu\u0165 k\u00a0j\u00eddlu, ale i\u00a0dal\u0161\u00ed nutkav\u00e9 touhy. V\u00fdzkum je st\u00e1le v\u00a0ran\u00e9 f\u00e1zi, ale sm\u011br je pozoruhodn\u011b konzistentn\u00ed. Utrp\u00ed s\u00a0masov\u00fdm n\u00e1stupem l\u00e9k\u016f i\u00a0zisky prodejc\u016f alkoholu, drog a\u00a0jin\u00fdch l\u00e1kadel?<\/p>\n

Ot\u00e1zky, na kter\u00e9 odpov\u00ed a\u017e praxe<\/p>\n

Pak je tu ot\u00e1zka kvality a\u00a0bezpe\u010dnosti. Semaglutid je peptid o\u00a031\u00a0aminokyselin\u00e1ch\u00a0\u2013 jednodu\u0161\u0161\u00ed ne\u017e velk\u00e9 biologick\u00e9 l\u00e9ky, ale slo\u017eit\u011bj\u0161\u00ed ne\u017e b\u011b\u017en\u00e1 tableta. Indick\u00fd regul\u00e1tor sice vy\u017eaduje od v\u00fdrobc\u016f vlastn\u00ed klinick\u00e9 studie, jen\u017ee p\u0159i sou\u010dasn\u00e9m vstupu \u010dty\u0159iceti firem na trh je t\u011b\u017ek\u00e9 zaru\u010dit u\u00a0v\u0161ech stejnou \u00farove\u0148 kvality. Chirurg Muffazal Lakdawala to pro BBC<\/a> vyj\u00e1d\u0159il p\u0159\u00edmo: \u201eNechceme, aby vedlej\u0161\u00ed \u00fa\u010dinky nekvalitn\u00edch kopi\u00ed po\u0161kodily pov\u011bst samotn\u00e9 molekuly.\u201c<\/p>\n

A kone\u010dn\u011b: v\u00a0Indii, kde se i\u00a0antibiotika b\u011b\u017en\u011b kupuj\u00ed bez p\u0159edpisu, hroz\u00ed zneu\u017e\u00edv\u00e1n\u00ed. Diabetolog Rahul Baxi pro BBC \u0159ekl, \u017ee pacienti p\u0159ich\u00e1zej\u00ed a\u00a0cht\u011bj\u00ed rychle zhubnout, proto\u017ee vid\u011bli videa na soci\u00e1ln\u00edch s\u00edt\u00edch. Kosmetick\u00e9 salony a\u00a0dietn\u00ed poradci bez opr\u00e1vn\u011bn\u00ed p\u0159edepisuj\u00ed vysok\u00e9 d\u00e1vky. S\u00a0ni\u017e\u0161\u00edmi cenami se tyto probl\u00e9my pravd\u011bpodobn\u011b zn\u00e1sob\u00ed. Indick\u00fd regul\u00e1tor l\u00e9k\u016f minul\u00fd t\u00fdden varoval<\/a> farmaceutick\u00e9 firmy p\u0159ed reklamou na hubnut\u00ed, kter\u00e1 slibuje dramatick\u00e9 v\u00fdsledky nebo bagatelizuje pot\u0159ebu diety a\u00a0pohybu.<\/p>\n

Co se t\u00fd\u010de p\u0159\u00edstupu k\u00a0nej\u00fa\u010dinn\u011bj\u0161\u00edm l\u00e9k\u016fm na obezitu, sv\u011bt se tedy pr\u00e1v\u011b rozd\u011blil na dv\u011b \u010d\u00e1sti. V\u00a0jedn\u00e9 z\u00a0nich za\u010d\u00edn\u00e1 experiment, jeho\u017e v\u00fdsledky nakonec ovlivn\u00ed i\u00a0tu druhou. Odpov\u011bdi na v\u011bt\u0161inu ot\u00e1zek, kter\u00e9 jsme tu polo\u017eili\u00a0\u2013 jak se zm\u011bn\u00ed stravov\u00e1n\u00ed, pohybov\u00e9 n\u00e1vyky, m\u00edra z\u00e1vislost\u00ed, rozlo\u017een\u00ed obezity ve spole\u010dnosti\u00a0\u2013, zat\u00edm nezn\u00e1me. Ale je celkem jasn\u00e9, kde je budeme moci naj\u00edt.<\/p>\n","protected":false},"excerpt":{"rendered":"V p\u00e1tek 21.\u00a0b\u0159ezna vypr\u0161el v\u00a0Indii patent na semaglutid, \u00fa\u010dinnou l\u00e1tku p\u0159\u00edpravk\u016f Ozempic a\u00a0Wegovy od d\u00e1nsk\u00e9ho v\u00fdrobce l\u00e9k\u016f Novo…\n","protected":false},"author":2,"featured_media":35444,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[8487,14811,9903,14812,5294,7604,9794,54,53,52],"class_list":{"0":"post-35443","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-svet","8":"tag-farmaceuticky-prumysl","9":"tag-glp-1","10":"tag-leky-na-hubnuti","11":"tag-novo-nordisk","12":"tag-obezita","13":"tag-ozempic","14":"tag-patent","15":"tag-svet","16":"tag-world","17":"tag-world-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116290647891080590","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/35443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=35443"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/35443\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/35444"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=35443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=35443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=35443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}